AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its cancer drugs, the pharmaceuticals giant said on Thursday as it continues to gauge the impact of ongoing investigations in the key growth market.

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China,

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with Chinese authorities.